Trials / Completed
CompletedNCT02229253
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | degarelix |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-10-04
- Completion
- 2017-10-04
- First posted
- 2014-09-01
- Last updated
- 2017-11-27
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02229253. Inclusion in this directory is not an endorsement.